Beth Eaby-Sandy
University of Pennsylvania
12 Papers
45 Citations
Beth Eaby-Sandy is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Nivolumab & non-small cell lung cancer (NSCLC). The author has an hindex of 6, co-authored 12 publications.
Chat about Author
Papers
Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
Stephen J Bagley,Shawn Kothari,Charu Aggarwal,Joshua Bauml,Evan W. Alley,Tracey L. Evans,John A. Kosteva,Christine Ciunci,Peter Gabriel,Jeffrey C. Thompson,Susan Stonehouse-Lee,Victoria Sherry,Elizabeth Gilbert,Beth Eaby-Sandy,Faith Mutale,Gloria Dilullo,Roger B. Cohen,Anil Vachani,Corey J. Langer +18 more
TL;DR: In a cohort of patients with NSCLC treated with nivolumab in routine practice, pretreatment NLR≥5 was associated with inferior outcomes, and it is unclear whether this marker is predictive or prognostic.
480
Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group.
Rebecca Wong,Rene Jean Bensadoun,Christine B. Boers-Doets,Jane Bryce,Alexandre Chan,Joel B. Epstein,Beth Eaby-Sandy,Mario E. Lacouture +7 more
TL;DR: There is insufficient evidence to support, and therefore the panel recommends against the use of trolamine, topical sulcrate, hyaluronic acid, ascorbic acid, silver leaf dressing, light-emitting diode lasers, Theta cream, dexpanthenol, calendula, proteolytic enzymes, sulcralfate, oral zinc, and pentoxifylline.
237
Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer
James P. Stevenson,Corey J. Langer,Robert A. Somer,Tracey L. Evans,Kumar Rajagopalan,Kimberly Krieger,Mona Jacobs-Small,Nikolas Dyanick,Barry Milcarek,Susan Coakley,Suzanne Walker,Beth Eaby-Sandy,Alexandre Hageboutros +12 more
TL;DR: The authors performed a phase 2 study of bevacizumab plus pemetrexed and carboplatin followed by maintenance bevacsumab in patients with advanced, nonsquamous nonsmall cell lung cancer.
23
P3.02c-028 Outcomes of Nivolumab in Elderly Patients (pts) with Non-Small Cell Lung Cancer (NSCLC): Topic: IT
Stephen J Bagley,Shawn Kothari,Charu Aggarwal,Joshua Bauml,Evan W. Alley,Tracey L. Evans,John A. Kosteva,Christine Ciunci,Jeffrey C. Thompson,Susan Stonehouse-Lee,Victoria Sherry,Elizabeth Gilbert,Beth Eaby-Sandy,Faith Mutale,Gloria Dilullo,Roger B. Cohen,Anil Vachani,Corey J. Langer +17 more
10
P3.02c-029 Immune-Related Adverse Events and Their Effect on Outcomes in Patients (pts) with Non-Small Cell Lung Cancer (NSCLC) Treated with Nivolumab: Topic: IT
Shawn Kothari,Stephen J Bagley,Charu Aggarwal,Joshua Bauml,Evan W. Alley,Tracey L. Evans,John A. Kosteva,Christine Ciunci,Jeffrey C. Thompson,Susan Stonehouse-Lee,Victoria Sherry,Elizabeth Gilbert,Beth Eaby-Sandy,Faith Mutale,Gloria Dilullo,Roger B. Cohen,Anil Vachani,Corey J. Langer +17 more
10